Warren – October 31, 2026 -- PTC Therapeutics (NASDAQ: PTCT) granted stock options on 9,620 shares and 11,535 restricted stock units to 13 new employees, with the options struck at $63.02 per share.

Compensation Committee approved the grants on Oct. 28 under Nasdaq's inducement exception

The awards were made under the Nasdaq inducement grant exception, Listing Rule 5635(c)(4). PTC describes them as material to each employee's decision to accept employment. The options are non-statutory.

Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.

Warren, N.J. – September 21, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc.

PTC targets Q4 2026 completion of rolling BLA submission for accelerated approval

The company confirmed that a rolling Biologics License Application submission to the FDA seeking accelerated approval of ST-920, also known as isaralgagene civaparvovec, is expected to be completed in the fourth quarter of 2026.